Corcept Therapeutics presents data from Momentum trial at ACC 2026

Corcept Therapeutics (CORT) presented late-breaking data from its Momentum trial examining the prevalence of endogenous hypercortisolism in patients with resistant hypertension at the 2026 American College of Cardiology Annual Scientific Session, ACC 2026. Momentum screened 1,086 patients with resistant hypertension and found that 27.3 percent, or 297 patients had hypercortisolism. This finding complements the results of Corcept’s Catalyst trial, which found hypercortisolism in 23.8 percent of the 1,057 patients screened with difficult-to-control type 2 diabetes. The prevalence of hypercortisolism in patients who had hemoglobin A1c of 7.5 percent or higher and were taking 3 or more blood pressure medicines was 32.6 percent in Momentum and 36.6 percent in Catalyst.